SCHEMBL4334935

SCHEMBL4334935

O=C(NCc1ccc(F)cc1)c1nc(-c2cccc(Cl)c2)n2ccccc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 2/20 0.47
RAB9A P51151 2/20 0.47
ALDH1A1 P00352 2/20 0.47
KDM4E B2RXH2 1/20 0.47
NPC1 O15118 1/20 0.47
HTT P42858 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
CNR2 P34972 3/20 0.44
CNR1 P21554 1/20 0.44
CCR1 P32246 1/20 0.44
CASP3 P42574 1/20 0.44
SENP8 Q96LD8 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
SENP6 Q9GZR1 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.44
TP53 P04637 2/20 0.44
LMNA P02545 1/20 0.43
MAPT P10636 1/20 0.43
POLB P06746 1/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4326415 0.93 KDM4E (0.49) PTGER4RAB9AALDH1A1KDM4ENPC1
SCHEMBL4331152 0.92 PTGER4 (0.50) PTGER4RAB9AALDH1A1KDM4ENPC1
SCHEMBL13578099 0.91 CCR1 (0.52) PTGER4RAB9AALDH1A1KDM4ENPC1
SCHEMBL4320324 0.90 CNR2 (0.51) PTGER4NPC1CNR2CNR1CCR1
SCHEMBL13578100 0.90 TP53 (0.51) PTGER4RAB9AALDH1A1KDM4ENPC1
SCHEMBL13578097 0.89 ALDH1A1 (0.55) PTGER4RAB9AALDH1A1KDM4ENPC1
SCHEMBL4326084 0.88 CNR2 (0.48) PTGER4RAB9AALDH1A1KDM4ENPC1
Trifluoroacetic Acid SCHEMBL4320038 0.87 CASP3 (0.49) PTGER4CNR2CNR1CCR1CASP3
SCHEMBL4332820 0.86 CNR2 (0.45) CNR2CNR1TP53LMNAMAPT
Trifluoroacetic Acid SCHEMBL4326117 0.85 TP53 (0.49) PTGER4RAB9AALDH1A1KDM4ENPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES MERCK & CO., INC. 2009-12-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090325936-A1 IMIDAZOPYRIDINE ANALOGS AS CB2 RECEPTOR MODULATORS, USEFUL IN THE TREATMENT OF PAIN, RESPIRATORY AND NON-RESPIRATORY DISEASES CNR2, CNR1, TRPV1 PTGER4 62/4885RAB9A 1558/4885ALDH1A1 2838/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.